MedRhythms Hires Joel Behnke as Chief Commercial Officer; Announces New Publications in Support of InTandem®

PORTLAND, Maine, Feb. 4, 2025 /PRNewswire/ -- MedRhythms, Inc. today announced that Joel Behnke has been hired as Chief Commercial Officer. Mr. Behnke brings over two decades of commercial leadership in medical devices to MedRhythms where he will drive sales and marketing efforts across the pipeline of products, with initial focus on commercialization of InTandem, the company's flagship neurorehabilitation system for chronic stroke gait impairment.

"Mr. Behnke is a highly respected and high caliber executive," said Brian Harris, MedRhythms' Co-Founder and CEO. "Joel has a strong track record of demonstrated success in scaling medical devices in rehabilitation, specializing in improving mobility in neurologic injury and disease states. His deep domain expertise combined with an action-focused, data-driven leadership style and a strong commitment to patients make him the ideal candidate to lead MedRhythms' commercial growth."

Mr. Behnke joins MedRhythms after serving as Vice President of Sales, Marketing & Strategy for the Advanced Rehabilitation Division at Bioventus. With more than 20 years of experience in the medical device industry, particularly in rehabilitation and neuromodulation, Mr. Behnke has an established reputation of driving profitable business growth. Most recently, he successfully led the divestiture of Bioventus' Advanced Rehabilitation business to private equity, showcasing his expertise in strategic leadership and operational excellence.

"MedRhythms' innovative product suite and pipeline hold immense potential to redefine the standard of care for patients with chronic diseases experiencing mobility impairments," said Mr. Behnke. "I'm excited to collaborate with this talented management team and apply my expertise to drive the expansion of MedRhythms' commercial initiatives."

Additionally, today MedRhythms announced two recent publications that address unmet needs and best practices in stroke rehabilitation, and assess the economic value of InTandem, respectively:

1. Multidisciplinary Delphi Panel on Rehabilitation Approaches and Unmet Needs for Chronic Stroke Walking Impairment and the Role of Rhythmic Auditory Stimulation, published in Cureus in August 2024.
2. One-year budget impact of InTandem™: a novel neurorehabilitation system for individuals with chronic stroke walking impairment, published in the Journal of Comparative Effectiveness Research in September 2024.

In the first study, an eight-expert Delphi panel identified areas of consensus in current practice patterns and treatment options for walking impairment after stroke, including the unmet rehabilitation needs in the chronic phase of recovery and the potential value of rhythmic auditory stimulation (RAS) in gait rehabilitation.

The second study is a budget impact analysis (BIA) of InTandem conducted based on a 1-million-member US third-party payer perspective over a one-year time horizon. The BIA concluded that "introduction of InTandem was projected to result in overall cost savings of $439,954 in one year."

"These studies and the recently announced Centers for Medicare and Medicaid Services (CMS) InTandem payment determination provide strong proof-points for the product and MedRhythms," said Mr. Behnke. "They will be important tools as we build relationships with patients, providers, and payers."

About MedRhythms
MedRhythms is pioneering the development of next-generation neurotherapeutics designed to improve walking, mobility and related functional outcomes via a proprietary, patented technology platform. The company's platform combines sensors, software, and music with advanced neuroscience to target neural circuitry. The company is developing a pipeline of products across a range of neurological conditions, including stroke, multiple sclerosis and Parkinson's disease. In 2021, the company partnered with Universal Music Group and raised a Series B financing round led by Morningside Ventures and Advantage Capital. MedRhythms is headquartered in Portland, Maine.

For more information, visit www.medrhythms.com.

MedRhythms and InTandem are trademarks of MedRhythms, Inc.

Forward-Looking Statements
THIS MANAGEMENT COMMENTARY CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO THE COMPANY THAT ARE BASED ON INFORMATION AVAILABLE TO US AS OF THE DATE HEREOF. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS ABOUT THE COMPANY'S BELIEFS, DESIGNS, ANTICIPATION, AIMS, GOALS, EXPECTATIONS AND POTENTIAL RESULTS ARE FORWARD-LOOKING STATEMENTS. IN ADDITION, THE WORDS "WILL," "MAY," "BELIEVE," "ANTICIPATE," "INTEND," "ESTIMATE," "EXPECT," "PROJECT," "PLAN," "SHOULD," "COULD," AND SIMILAR EXPRESSIONS, AND THEIR VARIATIONS AND NEGATIVES, AS THEY RELATE TO THE COMPANY OR THE FUTURE PERFORMANCE OF THE COMPANY, ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. SUCH FORWARD LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES, ASSUMPTIONS AND OTHER IMPORTANT FACTORS THAT COULD CAUSE THE COMPANY'S ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH FORWARD LOOKING STATEMENTS. THIS MANAGEMENT COMMENTARY SPEAKS ONLY AS OF THE DATE HEREOF AND THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO UPDATE THIS COMMENTARY IN THE FUTURE.

Contact
[email protected]

SOURCE MedRhythms